Independent
Tenure on this board
4.7 yrs
Meeting calendar
OVID · Annual meeting · Wednesday, July 9, 2025
Ovid Therapeutics Inc
2 nominees · 4 ballot items.
Election of two Class II directors; advisory vote on executive compensation; ratification of the independent registered public accounting firm; and approval of a series of alternate amendments to our certificate of incorporation to effect a reverse stock split.
Market cap
$500M
1Y TSR
+691.4%
Board grade
C+
Record date
May 19, 2025
Filing
DEF 14A
Meeting concluded · Jul 9, 2025
Follow how the vote landed and what changed on Ovid Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot4
- 1
Election of Directors
ManagementBoard: FORElection of two Class II director nominees to serve three-year terms.
- 2
Advisory Vote on Executive Compensation
ManagementBoard: FORNon-binding advisory vote on the compensation of the named executive officers as disclosed in this proxy statement.
- 3
Ratification of the Selection of the Independent Registered Public Accounting Firm
ManagementBoard: FORRatification of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
- 4
Approval of a Series of Alternate Amendments to Our Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split
ManagementBoard: FORApproval of amendments to allow a reverse stock split of the common stock in a range from 1-for-10 to 1-for-40, at the Board’s option, with the Board authorized to select the ratio.
Director elections
Nominees on the ballot2
Independent
Tenure on this board
9.1 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 5.7% | 10,714,000 | $24M |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 5.7% | 10,714,000 | $24M |
| 3 | Affinity Asset Advisors, LLC | 5.7% | 10,636,318 | $24M |
| 4 | EVENTIDE ASSET MANAGEMENT, LLC | 5.3% | 9,916,911 | $22M |
| 5 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.3% | 6,163,781 | $14M |
| 6 | BALYASNY ASSET MANAGEMENT L.P. | 3.0% | 5,533,073 | $12M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 2.8% | 5,258,246 | $12M |
| 8 | ADAR1 Capital Management, LLC | 2.4% | 4,544,113 | $10M |
| 9 | Saturn V Capital Management LP | 2.2% | 4,166,666 | $9M |
| 10 | FEDERATED HERMES, INC. | 1.9% | 3,571,000 | $8M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Ovid Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Xoma Royalty CorpXOMA
Annual meeting·Jul 13, 2026·$533M
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$427M
Trubridge IncTBRG
Special meeting·Jul 7, 2026·$393M
Achieve Life Sciences IncACHV
Annual meeting·Jul 2, 2026·$670M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Esperion Therapeutics IncESPR
Special meeting·Jul 8, 2026·$814M
Reference
Frequently asked questions
- When is the Ovid Therapeutics Inc 2025 annual meeting?
- Ovid Therapeutics Inc (OVID) holds its 2025 annual shareholder meeting on Wednesday, July 9, 2025.
- What is the record date for the Ovid Therapeutics Inc 2025 meeting?
- The record date for the Ovid Therapeutics Inc 2025 meeting is Monday, May 19, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Ovid Therapeutics Inc's 2025 meeting?
- The board is presenting 2 director nominees at the Ovid Therapeutics Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Ovid Therapeutics Inc 2025 meeting?
- Shareholders will vote on 4 proposals at the Ovid Therapeutics Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.